drugset / Trial / NCT02258971
Metabolism and Pharmacokinetics of [14C] BEA 2180 BR Administered Orally Compared to [14C] BEA 2180 BR Administered Intravenously in Healthy Male Volunteers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Primary objectives: To determine the basic pharmacokinetics of BEA 2180 BR, its metabolites CD 1975 ZW and CD 1976 ZW and radioactivity including excretion mass balance, excretion pathways and metabolism following the oral and intravenous administration of \[14C\] BEA 2180 BR Secondary objectives: To determine safety and tolerability following single dose oral and iv administration of BEA 2180 BR in healthy male volunteers.
Timeline
- Start
- 2007-03
- Primary completion
- 2007-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BEA 2180 BR | Unknown | 500 ug | Oral |
| Subject | BEA 2180 BR | Unknown | 1200 ug | Oral |
Indications
No indication recorded.